KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Deferred Taxes (2021 - 2025)

Pacific Biosciences Of California's quarterly Deferred Taxes came in at -$546000.0 in Q1 2025, down 166.34% quarter-over-quarter from -$205000.0 in Q4 2024.

Pacific Biosciences Of California has reported Deferred Taxes for 4 years, with the latest figure at -$546000.0 in Q1 2025.

  • For the quarter ending Q1 2025, Deferred Taxes changed N/A year-over-year to -$546000.0; the trailing twelve-month figure through Dec 2025 stood at -$546000.0 (down 166.34% YoY), and the FY2025 full-year result was -$546000.0, down 166.34% from the prior year.
  • Deferred Taxes for Q1 2025 stood at -$546000.0, down from -$205000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $1.2 million in Q4 2021, with the low at -$718000.0 in Q4 2023.
  • Average Deferred Taxes over 4 years is -$73500.0, with a median of -$375500.0 recorded in 2024.
  • Peak annual rise in Deferred Taxes reached 71.45% in 2024, while the deepest fall reached 71.45% in 2024.
  • Tracing PACB's Deferred Taxes over 4 years: stood at $1.2 million in 2021, then sank by 161.11% to -$718000.0 in 2023, then soared by 71.45% to -$205000.0 in 2024, then sank by 166.34% to -$546000.0 in 2025.
  • The last three Deferred Taxes figures came in at -$546000.0 (Q1 2025), -$205000.0 (Q4 2024), and -$718000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -33.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -101.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -9.40 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 300,000.00
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -16.70 Mn
10 Pacific Biosciences Of California 481.66 Mn 205.70 Mn 12.84 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 -546,000.00
Dec 31, 2024 -205,000.00
Dec 31, 2023 -718,000.00
Dec 31, 2021 1.18 Mn